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Abstract: Starting from ( )-trans- and ( )-cis-3-hydroxymethyl-1-indanol, novel 6-substituted 
purinylcarbanucleoside derivatives of indan (5, 6, 9, 10, 15 and 17) were synthesized through a 
key coupling reaction with 6-chloropurine under Mitsunobu conditions. Suzuki–Miyaura 
reactions of the protected 6-chloropurine derivative with different arylboronic acids afforded the 
corresponding 6-arylpurinylcarbanucleoside derivatives. Finally, three new 5-
halouracilcarbanucleosides (19, 20 and 21) were prepared by reaction of uracilcarbanucleoside 
18 with different N-halosuccinimides. All of the new analogues were evaluated for antiviral 
activity against a wide variety of viruses. 
 
 








Carbocyclic nucleosides (carbanucleosides) are analogues of nucleosides in which a 
methylene group has replaced the oxygen atom in the furanose ring.
2
 These analogues 
show similar biological activities to the parent nucleosides and have higher metabolic 
and chemical stability against different phosphorylases, hydrolases and cleaving 
agents.
3
 Of the different carbanucleosides prepared to date, carbovir
4
 has shown 
significant anti-HIV activity through the selective inhibition of HIV-1 reverse 
transcriptase. Its derivative abacavir
5
 is equally potent but is less toxic, has greater 
bioavailability and has been approved by the FDA for the treatment of HIV infection. 
Both of these compounds are cyclopentenyl carbanucleosides and their anti-HIV 
capacity has stimulated the development of new carbanucleosides in which the 















In the last two years our research group has prepared different series’ of 
carbanucleosides derived from indan and these bear purine and pyrimidine bases and are 




 These were synthesised 
with the aim of increasing the liposolubility of the compounds and to facilitate their 
access to the central nervous system, a significant reservoir of HIV and other viruses.
8
 
Some of these compounds showed interesting cytostatic activity, particularly the 6-




As a logical continuation of our research into the preparation and pharmacological 
evaluation of novel carbanucleosides derived from indan, we report here the synthesis 
of a new series of nucleosides in which the link between the carbacycle bearing the base 
(purine or pyrimidine) and the hydroxyl group is the same as in natural nucleosides. 
More specifically, we report the synthesis and antiviral and cytostatic activities of a 
series of indanylcarbanucleosides bearing purine and pyrimidine bases. 
Results and discussion 
Retrosynthetic analysis (Scheme 1) led to the choice of diol trans-1 as the starting 
material for the prepatration of the different purine derivatives. Appropriate 
functionalization of trans-1 enables the coupling with 6-chloropurine under Mitsunobu 
conditions. This reaction leads to inversion of the configuration at the carbon bearing 
the secondary hydroxyl group and gives the key intermediate with a cis disposition. 
Acid hydrolysis of this compound gave analogue 5, which on replacement of the chloro-
substituent of the purine ring gave the 6-substituted purinylcarbanucleosides 6, 15 and 
17, while Suzuki–Miyaura cross-coupling with appropriate boronic acids would give 6-
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Diol trans-1 was obtained from phenylsuccinic anhydride by Friedel–Crafts reaction 
with aluminium trichloride in 1,2-dichloroethane followed by esterification with 
methanol in sulphuric acid
10
 and treatment with lithium borohydride in tetrahydrofuran. 
In this way a 17:83 mixture of (±)-trans-1 and (±)-cis-2 was obtained and this was 
efficiently resolved by chromatography on silica gel.
7a
 Diol (±)-trans-1 is the starting 
material required to obtain analogues with a cis disposition, but this compound was only 
obtained in small quantities. As a result, we decided to use the diol (±)-cis-2 as a 
starting material as this could be transformed into (±)-trans-1 through a Mitsunobu 
reaction with benzoic acid. Protection of the primary alcohol in trans-1 was achieved by 
enzymatic transesterification with vinyl acetate using Candida antarctica lipase 
(Novozym® 435)
11
 to give the monoacetylated derivative 3 as the only product in 93% 
yield. 6-Chloropurine was condensed with 3 by a standard Mitsunobu reaction,
12
 in the 
presence of triethylphosphine and diethyl azodicarboxylate, to give the key intermediate 
4 in 46% yield. Treatment of 4 with 2N hydrochloric acid in tetrahydrofuran gave 6-
chloropurinylcarbanucleoside 5 in 40% yield. Subsequent treatment of 5 with MeONa 
in MeOH gave 6-methoxypurinylcarbanucleoside 6 in 99% yield. On the other hand, on 
following the conditions reported by Hocek and co-workers,
13
 the chloro-substituent in 
position 6 of the purine was replaced in a Suzuki–Miyaura cross coupling reaction with 
4 and different arylboronic acids in dry toluene containing 
tetrakis(triphenylphospine)palladium as a catalyst and potassium carbonate as a base.
14
 
This procedure gave 46–65% yields of compounds 7 and 8. Deprotection of these 
compounds with MeONa in MeOH afforded the 6-arylpurinylcarbanucleosides 9 and 10 
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The primary alcohol of cis-2 was protected by reaction with tert-butyldimethylsilyl 
chloride and imidazole in dichloromethane,
15
 and the secondary alcohol of the resulting 
compound 11 was reacted with benzoic acid under Mitsunobu conditions to give 
compound 12 in 75% yield. Compound 12 had the required trans disposition. 
Deprotection of the secondary alcohol using MeONa in MeOH gave the key 
intermediate 13 in 95% yield. Compound 13 was used in the coupling with 6-
chloropurine, through a Mitsunobu reaction, to give 6-chloropurinylcarbanucleoside 14 
in 24% yield (with a cis disposition). Treatment of 14 with 0.25 N NaOH in 1,4-dioxane 
afforded the 6-hydroxypurinylcarbanucleoside 15 in one step and in 73% yield, while 
treatment with N-cyclopropylamine in tetrahydrofuran followed by deprotection with a 
3:1 mixture of trifluoroacetic acid/water gave the 6-methoxypurinylcarbanucleoside 17 























































Finally, the 5-halouracilcarbanucleosides 19, 20 and 21 (Scheme 4) were obtained by 
reaction of uracilcarbanucleoside 18, previously reported by ourselves,
16
 with the 































Compounds 5, 6, 9, 10, 15, 17, 19, 20 and 21 were evaluated for antiviral activity
18
 
against a wide variety of viruses, including Cytomegalovirus (AD 169 and Davis 
strains), Varicella-zoster virus (OKA and 07/1 strains), Herpes simplex virus type 1 
(strain KOS), Herpes simplex virus type 2 (strain G), Vaccinia virus and Vesicular 
stomatitis virus in HEL cell cultures; Coxsackie virus B4, Respiratory syncytial virus 
and Vesicular stomatitis virus in HeLa cell cultures; Para-influenza-3 virus, Sindbis, 
Coxsackie virus B4 and Punta Toro virus in Vero cell cultures; Influenza A virus 
(H1N1 and H3N2 subtypes) and Influenza B virus in MDCK cell cultures; and Feline 
Corona virus and Feline Herpes Virus in CRFK cell cultures. The most outstanding 
results were obtained for compound 10, which showed moderate antiviral effects against 
Varicella-zoster virus (OKA strain), Vaccinia virus, Herpes simplex virus-1 (KOS) and 
Herpes simplex virus-2 (G) in HEL cell cultures with EC50 values of 6.0, 12, 12 and 12 
µg/mL, respectively, and compounds 5 and 9, which showed moderate antiviral effects 
against Coxsackie virus B4 in Vero cell cultures with EC50 values of 12 µg/mL. 
 
Conclusions 
In summary, we have described the synthesis of nine novel carbocyclic nucleosides that 
are indan derivatives (5, 6, 9, 10, 15, 17, 19, 20 and 21) with a pseudosugar based on 
indanol, a template in which the double bond of the cyclopentenyl nucleosides is 
embedded in a benzene ring. Evaluation of the antiviral activity of these compounds 




Silica gel (230 mesh) was purchased from Merck. All other chemicals used were of 
reagent grade and were obtained from Aldrich Chemical Co. Melting points were 
determined using a Reichert Kofler Thermopan or in capillary tubes on a Büchi 510 
apparatus, and are uncorrected. Infrared spectra were recorded on a Perkin-Elmer 1640-
FT spectrophotometer. 
1
H NMR spectra (300 MHz) and 
13
C NMR spectra (75.47 MHz) 
were recorded on a Bruker AMX spectrometer, using TMS as internal standard 
(chemical shifts ( ) in ppm, J in Hz). Elemental analyses were obtained on a Perkin-
Elmer 240B microanalyser by the Microanalysis Service of the University of Santiago 
de Compostela. Flash chromatography was performed on silica gel (Merck 60, 230–240 
mesh) and analytical TLC on pre-coated silica gel plates (Merck 60 F254, 0.25 mm). 
( )-trans-3-Hydroxymethyl-1-indanol, 1,and ( )-cis-3-hdroxymethyl-1-indanol, 2. 
A solution of methyl-3-oxo-1-indanecarboxylate
6a
 (12.48 g, 70.61 mmol) in dry THF 
was added dropwise under argon to a suspension of LiBH4 (8.09 g, 353.06 mmol) in the 
same solvent. The mixture was stirred for 12 h and saturated aqueous (40 mL) was 
added dropwise at 0 C. The resulting mixture was filtered through Celite and the 
aqueous and organic phases were separated. The aqueous phase was extracted with 
AcOEt (3  100 mL) and the combined organic phases were washed with saturated 
NaCl solution, dried over anhydrous Na2SO4, and concentrated under vacuum. 
Chromatography of the resulting yellow oil on a column of silica gel (295 g) with 40:1 
CH2Cl2/
i
PrOH as eluent afforded cis-2 in the early fractions [as an oil that 
spontaneously solidified; 8.22 g, 50.06 mmol, yield 78%; M.p. 78-80 C 
(Et2O/cyclohexane)] and trans-1 in the late fractions (as a yellow oil; 1.76 g, 10.71 
mmol, yield 15%). 
( )-cis-2. 
IR (KBr):  = 3250, 2984, 2933, 1461, 1407, 1379, 1281, 1263, 1211, 1173, 1067, 




H NMR (CDCl3):  = 1.74-1.81 (m, 1H, 2 -H), 2.20-
2.40 (m, 1H, -OH, exchangeable with D2O), 2.49-2.57 (m, 1H, 2 -H), 3.20-3.50 (m, 
1H, 3 -H), 3.40-3.50 (b.s., 1H, -OH, exchangeable with D2O), 3.72-3.83 (m, 2H, 
CH2OH), 4.91-5.01 (m, 1H, 1 -H), 7.18-7.35 (m, 4H, ArH). 
13
C NMR (CDCl3):  = 
39.37 (CH2), 45.63 (CH), 65.60 (CH2), 74.83 (CH), 124.56, 125.24, 128.02 and 129.17 
(CH), 143.77 and 146.43 (C). Anal. calcd. for C10H12O2: C, 73.15; H, 7.37. Found: C, 
73.41; H, 7.17. 
( )-trans-1. 





H NMR (CDCl3):  = 2.02-2.13 (m, 1H, 2 -H), 2.24-2.34 (m, 1H, 2 -H), 
3.43-3.50 (m, 1H, 3 -H), 3.68-3.70 (m, 2H, CH2OH), 5.22-5.26 (m, 1H, 1 -H), 7.23-
7.40 (m, 4H, ArH). 
13
C NMR (CDCl3):  = 47.06 (CH2), 52.87 (CH), 73.73 (CH2), 
82.85 (CH), 132.20, 132.38, 135.36 and 136.31 (CH), 151.12 and 153.27 (C). Anal. 
calcd. for C10H12O2: C, 73.15; H, 7.37. Found: C, 73.36; H, 7.13. 
( )-trans-3-Hydroxy-1-indanylmethyl acetate, 3. 
A suspension of the lipase Novozym® 435 (0.140 g; 0.321 mmol) and diol 1 (0.550 g; 
3.35 mmol) in THF (25 mL), at 0º C under an argon atmosphere, was added a solution 
of vinyl acetate (0.32 mL; 3.35 mmol) in THF (30 mL). The mixture was stirred for 4 h 
at 0ºC and then at room temperature for 68 h. The mixture was filtered through Celite 
and the solvent was removed under reduced pressure to give a yellow oil, which was 
purified by column chromatography on silica gel (30.4 g), using hexane/AcOEt (8:1) as 
eluent, to give 3 as a colourless oil (0.300 g; Yield 54%). IR (NaCl): υ = 3385, 1734, 




H NMR (CDCl3): δ = 2.06 (s, 3H, 
CH3), 2.17-2.27 (m, 2H, 2β-H + 2α-H), 3.64-3.70 (m, 1H, 1β-H), 4.10-4.25 (m, 2H, 
CH2OAc), 5.28-5.33 (m, 1H, 3α-H), 7.26-7.45 (m, 4H, ArH). 
13
C NMR (CDCl3): δ = 
21.38 (CH3), 40.10 (CH2), 42.24 (CH), 67.82 (CH2), 75.46 (CH), 124.98, 125.14, 
128.29 and 129.14 (CH), 143.40, 145.61, 171.54 (C). Anal. calcd. for C12H14O3: C, 
69.88; H, 6.84. Found: C, 70.03; H, 6.99. 
 
( )-cis-3-(6-Chloro-9H-purin-9-yl)indanylmethyl acetate, 4. 
To a solution of 3 (0.42 g; 2.03 mmol), PPh3 (1.07 g; 4.06 mmol) and 6-chloropurine 
(0.63 g; 4.06 mmol) in THF (20 mL), under an argon atmosphere at 0ºC, was added 
dropwise a solution of DEAD (1.86 mL; 4.06 mmol) in THF (15 mL). The mixture was 
stirred at 0ºC for 1 h and at room temperature for 65 h. The solvent was removed under 
reduced pressure to give a solid, which was purified by column chromatography on 
silica gel (113 g), using hexane/AcOEt (2:1) as eluent, to give an oil that crystallised 
spontaneously to give a colourless solid (0.17 g; Yield 46%). This product was 
identified as ( )-cis-3-(6-chloro-9H-purin-9-yl)indanylmethyl acetate, 4. M.p.: 35-38ºC 
(pentane). IR (KBr): υ = 2979, 1731, 1591, 1578, 1557, 1497, 1436, 1402, 1354, 1336, 




H NMR (CDCl3):  = 2.05 (s, 3H, CH3), 2.06-2.17 (dt, 
1H, J(t) = 13.64 Hz, J(d) = 7.75 Hz, 2 -H), 3.05-3.17 (dt, 1H, J(t) = 13.64 Hz, J(d) = 8.29 
Hz, 2 -H), 3.60-3.71 (m, 1H, 1 -H), 4.26-4.34 (Part A of an ABM system, 1H, JAB = 
11.72 Hz, JAM = 6.90 Hz, -CHHOAc), 4.38-4.45 (Part B of an ABM system, 1H, JBA = 
11.72 Hz, JBM = 6.62 Hz, -CHHOAc), 6.24-6.31 (t, 1H, J = 8.29 Hz, 3 -H), 7.05-7.08 
(d, 1H, J = 8.0 Hz, ArH), 7.26-7.44 (m, 3H, ArH), 7.99 (s, 1H, 8'-H), 8.77 (s, 1H, 2'-H). 
13
C NMR (CDCl3):  = 20.34 (CH3), 37.12 (CH2), 41.50 (CH), 57.76 (CH), 65.93 
(CH2), 123.88, 124.26, 127.99 and 129.17 (CH), 131.28 (C), 138.88 (C), 142.66 (C), 
143.20 (CH), 150.66 (C), 151.44 (CH), 156.21 (C) and 170.40 (C). Anal. calcd. for 
C17H15ClN4O2: C, 59.57; H, 4.41; N, 16.34. Found: C, 59.36; H, 4.73; N, 16.56. 
( )-cis-3-(6-Chloro-9H-purin-9-yl)-1-indanylmethanol, 5. 
To a solution of 4 (0.175 g; 0.510 mmol) in THF was added 2N HCl (10 mL) and the 
mixture was stirred for 20 h at 40ºC. The mixture was neutralised with 2N NaOH (12 
mL) and the solvent was removed under reduced pressure followed by several 
coevaporations with toluene and ethanol. This process gave a colourless solid, which 
was purified by column chromatography on silica gel (50 g), using hexane/AcOEt (1:3) 
as eluent, to give compound 5 as a colourless solid (0.06 g; Yield 40%). IR (KBr): υ = 





(CDCl3):  = 2.27-2.36 (dt, 1H, J(t) = 13.97 Hz, J(d) = 6.53 Hz, 2β-H), 3.03-3.13 (dt, 1H, 
J(t) = 13.98 Hz, J(d) = 8.81 Hz, 2α-H), 3.52-3.60 (m, 1H, 1β-H), 3.95-4.12 (m, 2H, 
CH2OH), 6.25-6.30 (t, 1H, J(t) = 6.81 Hz, 3β-H), 7.02-7.05 (d, 1H, J(d) = 7.61 Hz, ArH), 
7.24-7.29 (m, 1H, ArH), 7.37-7.42 (t, 1H, J(t) = 7.56 Hz, ArH), 7.43-7.47 (t, 1H, J(t) = 
7.45 Hz, ArH), 8.12 (s, 1H, 8'-H), 8.75 (s, 1H, 2'-H). 
13
C NMR (CDCl3):  = 36.19 
(CH2), 45.28 (CH), 58.63 (CH), 64.81 (CH2), 124.47, 124.68, 128.23 and 129.66 (CH), 
131.71 (C), 140.11 (C), 144.02 (C), 144.52 (CH), 150.99 (C), 151.81 (CH). Anal. calcd. 
for C15H13ClN4O: C, 59.91; H, 4.36; N, 18.63. Found: C, 60.15; H, 4.11; N, 18.40. 
( )-cis-3-(6-Methoxy-9H-purin-9-yl)-1-indanylmethanol, 6. 
To a solution of 5 (0.030 g; 0.101 mmol) in MeOH (10 mL) was added, under an argon 
atmosphere, MeONa (0.11 mL; 0.11 mmol) and the mixture was stirred for 6 h at room 
temperature. The solvent was removed under reduced pressure and the residue was 
purified by column chromatography on silica gel (3.15 g), using CH2Cl2/isopropanol 
(30:1) as eluent, to give 6 as a colourless solid (0.030 g; Yield 99%). IR (NaCl): υ = 




H NMR (CDCl3):  = 1.65 (s, 3H, 
CH3CO), 2.33-2.42 (dt, 1H, J(t) = 13.96 Hz, J(d) = 6.98 Hz, 2β-H), 3.00-3.11 (dt, 1H, J(t) 
=13.94 Hz, J(d) = 8.82 Hz, 2α-H), 3.52-3.60 (m, 1H, 1β-H), 3.90-4.01 (m, 2H, CH2OAc), 
4.19 (s, 3H, OCH3), 6.17-6.22 (t, 1H, J(t) = 7.87 Hz, 3β-H), 7.01-7.04 (d, 1H, J(d) = 7.58 
Hz, ArH), 7.23-7.31 (m, 1H, ArH), 7.36-7.46 (m, 2H, ArH), 7.88 (s, 1H, 2'-H), 8.51 (s, 
1H, 8'-H). 
13
C NMR (CDCl3):  = 35.84 (CH2), 45.16 (CH), 54.08 (CH3), 58.41 (CH), 
64.82 (CH2), 124.40, 124.83, 127.92 and 129.22 (CH), 140.34 (CH), 140.58 (CH), 
143.59 (C), 144.06 (C), 151.73 (CH), 160.99 (C). Anal. calcd. for C16H16N4O2: C, 
64.85; H, 5.44; N, 18.91. Found: C, 65.16; H, 5.29; N, 19.13. 
( )-cis-3-(6-Phenyl-9H-purin-9-yl)-1-indanylmethyl acetate, 7. 
A mixture of 4 (0.154 g; 0.83 mmol), K2CO3 (0.085 g; 0.675 mmol), 6-phenylboronic 
acid (0.094 g; 0.675 mmol) and Pd(PPh3)4 (0.046 g) in anhydrous toluene (80 mL) 
under an argon atmosphere was stirred for 12 h at 100ºC. The solvent was removed by 
vacuum distillation and the residue was purified by column chromatography on silica 
gel (48 g), using hexane/AcOEt (4:1) as eluent, to give 7 as a yellow oil, which 
crystallised spontaneously as a colourless solid (0.08 g; Yield 46%). M.p.: 38-41ºC 
(CHCl3/Hexane). IR (KBr): υ = 3418, 2919, 1734, 1649, 1560, 1536, 1457, 1351, 1223, 




H NMR (CDCl3):  = 2.05 (s, 3H, CH3), 2.09-2.21 (dt, 1H, J(t) = 
13.52 Hz, J(d) = 7.77 Hz, 2 -H), 3.08-3.20 (dt, 1H, J(t) = 13.52 Hz, J(d) = 8.18 Hz, 2 -
H), 3.62-3.73 (m, 1H, 1 -H), 4.35-4.42 (Part A of an ABM system, 1H, JAB = 11.11 Hz, 
JAM = 6.30 Hz, -CHHOAc), 4.44-4.51 (Part B of an ABM system, 1H, JBA = 11.11 Hz, 
JBM = 5.59 Hz, -CHHOAc), 6.31-6.38 (t, 1H, J = 7.89 Hz, 3 -H), 7.10-7.13 (d, 1H, J = 
7.62 Hz, ArH), 7.26-7.61 (m, 6H, ArH), 7.98 (s, 1H, 8'-H), 8.78-8.81 (d, 2H, J = 7.63 
Hz, ArH), 9.06 (s, 1H, 2'-H). 
13
C NMR (CDCl3):  = 21.31 (CH3), 38.29 (CH2), 42.46 
(CH), 58.02 (CH), 66.97 (CH2), 124.94, 125.15, 128.83, 129.10, 129.88 and 130.20 
(CH), 131.43 (C), 136.08 (C), 143.06 (CH), 143.61 (C), 152.83 (CH) and 171.34 (C). 
Anal. calcd. for C23H20N4O2: C, 71.86; H, 5.24; N, 14.57. Found: C, 71.61; H, 5.03; N, 
14.80. 
( )-cis-3-[6-(4'-Chloro)phenyl-9H-purin-9-yl)-1-indanylmethyl acetate, 8. 
Reaction of 4 with 6-chlorophenylboronic acid, following an identical procedure to that 
described in section 5.7, gave 8 as a clear oil that spontaneously crystallised to a 
colourless solid. (Yield 65%). M.p. 60-63ºC (CHCl3/Hexane). IR (KBr): υ = 3412, 




H NMR (CDCl3):  = 2.04 (s, 3H, CH3), 2.09-2.19 (dt, 1H, J(t) = 13.58 Hz, J(d) = 7.70 
Hz, 2 -H), 3.07-3.17 (dt, 1H, J(t) = 13.58 Hz, J(d) = 8.10 Hz, 2 -H), 3.64-3.71 (m, 1H, 
1 -H), 4.35-4.41 (Part A of an ABM system, 1H, JAB = 11.11 Hz, JAM = 6.30 Hz, -
CHHOAc), 4.43-4.48 (Part B of an ABM system, 1H, JBA = 11.11 Hz, JBM = 5.58 Hz, -
CHHOAc), 6.30-6.35 (t, 1H, J = 7.85 Hz, 3 -H), 7.09-7.11 (d, 1H, J = 7.60 Hz, ArH), 
7.26-7.49 (m, 3H, ArH), 7.50-7.53 (d, 2H, J = 8.57 Hz, ArH), 7.97 (s, 1H, 8'-H), 8.78-
8.81 (d, 2H, J = 8.57 Hz, ArH), 9.02 (s, 1H, 2'-H). 
13
C NMR (CDCl3):  = 21.27 (CH3), 
38.21 (CH2), 42.47 (CH), 58.07 (CH), 66.96 (CH2), 124.91, 125.17, 128.83, 129.31, 
129.91 and 131.52 (CH), 131.58 (C), 134.56 (C), 137.67 (C), 140.37 (C), 143.22 (CH), 
143.63 (C), 152.76 (CH), 153.19 (C), 154.02 (C) and 171.30 (C). Anal. calcd. for 
C23H19ClN4O2: C, 65.95; H, 4.57; N, 13.38. Found: C, 66.22; H, 4.35; N, 13.57. 
( )-cis-3-(6-Phenyl-9H-purin-9-yl)-1-indanylmethanol, 9. 
To a solution of 7 (0.05 g; 0.13 mmol) in MeOH (5 mL), under an argon atmosphere, 
was added powdered 95% MeONa (0.015 g; 0.264 mmol) and the mixture was stirred 
for 20 h. The solution was neutralised by the addition of Dowex 50 × 8 (H
+
) resin (ca. 
100 mg) and the mixture was stirred for 20 min. The resin was filtered off and washed 
with MeOH saturated with ammonia (10 mL) and MeOH (10 mL). The filtrates were 
combined and concentrated to dryness. The resulting colourless solid was purified by 
column chromatography on silica gel (6 g), using hexane/AcOEt (1:2) as eluent, to give 
9 as a colourless solid. (0.034 g; Yield 68%). M.p. 53-56ºC (CHCl3/Hexane). IR (KBr): 
υ = 3378, 2921, 1654, 1562, 1499, 1488, 1457, 1416, 1399, 1350, 1325, 1265, 1218, 




H NMR (CDCl3):  = 2.28-2.40 (dt, 1H, J(t) = 
13.85 Hz, J(d) = 7.10 Hz, 2 -H), 2.95-3.07 (dt, 1H, J(t) = 13.85 Hz, J(d) = 8.70 Hz, 2 -
H), 3.44-3.54 (m, 1H, 1 -H), 3.88-3.94 (Part A of an ABM system, 1H, JAB = 10.74 Hz, 
JAM = 4.12 Hz, -CHHOH), 3.99-4.05 (Part B of an ABM system, 1H, JBA = 10.74 Hz, 
JBM = 6.377 Hz, -CHHOH), 6.19-6.26 (t, 1H, J = 7.56 Hz, 3 -H), 6.97-7.01 (d, 1H, J = 
7.56 Hz, ArH), 7.08-7.53 (m, 6H, ArH), 8.03 (s, 1H, 8'-H), 8.67-8.71 (d, 2H, J = 7.68 
Hz, ArH), 8.93 (s, 1H, 2'-H). 
13
C NMR (CDCl3):  = 36.00 (CH2), 45.16 (CH), 58.09 
(CH), 64.84 (CH2), 124.36 (CH), 124.48 (C), 128.01, 128.11, 128.58, 128.93, 129.32 
and 129.70 (CH), 130.91 (C), 135.52 (C), 140.60 (C), 143.36 (CH), 143.68 (C), 152.06 
(CH), 154.98 (C). Anal. calcd. for C21H18N4O: C, 73.67; H, 5.30; N, 16.36. Found: C, 
73.30; H, 5.51; N, 16.61. 
( )-cis-3-[(6-(4'-Chloro)phenyl-9H-purin-9-yl)-1-indanylmethanol, 10. 
The same procedure as described in section 5.9 was used to prepare 10 from 8. (Yield 
71%). M.p. 56-59ºC (CHCl3/Hexane). IR (KBr): υ = 2922, 1582, 1518, 1497, 1485, 




H NMR (CDCl3):  = 
1.19-1.23 (b.s., 1H, OH exchangeable with D2O), 2.33-2.45 (dt, 1H, J(t) = 13.85 Hz, J(d) 
= 7.02 Hz, 2 -H), 3.05-3.17 (dt, 1H, J(t) = 13.85 Hz, J(d) = 7.67 Hz, 2 -H), 3.59-3.64 
(m, 1H, 1 -H), 3.99-4.15 (m, 2H, CH2OH), 6.28-6.35 (m, 1H, 3 -H), 7.05-7.08 (d, 1H, 
J = 7.55 Hz, ArH), 7.26-7.47 (m, 3H, ArH), 7.51-7.53 (d, 2H, J = 8.66 Hz, ArH), 8.12 
(s, 1H, 8'-H), 8.78-8.81 (d, 2H, J = 8.66 Hz, ArH), 8.99 (s, 1H, 2'-H). 
13
C NMR 
(CDCl3):  = 36.09 (CH2), 42.23 (CH), 58.26 (CH), 64.97 (CH2), 124.47, 124.58, 
128.19, 128.93, 129.50 and 131.11 (CH), 131.43 (C), 134.13 (C), 137.27 (C), 140.66 
(C), 143.56 (CH), 143.70 and 152.17 (C). Anal. calcd. for C21H17ClN4O: C, 66.93; H, 
4.55; N, 14.87. Found: C, 67.19; H, 4.76; N, 14.59. 
( )-cis-3-(tert-Butyldimethylsilyloxy)methylindanol, 11. 
To a suspension of diol 2 (1.6 g; 8.37 mmol) and imidazole (1.13 g; 16.74 mmol) in 
anhydrous dichloromethane (60 mL) was added, at 0ºC under an argon atmosphere, a 
solution of tert-butyldimethylsilyl chloride (1.35 g; 9.21 mmol) in anhydrous 
dichloromethane (20 mL). The mixture was cooled to 0-5ºC and stirred for 24 h. The 
mixture was allowed to warm up to room temperature and stirred for 1 h. 
Dichloromethane (60 mL) was added and the solution was extracted NaHCO3 (80 mL). 
The aqueous phase was extracted with dichloromethane (3 × 50 mL) and the combined 
organic phases were washed with saturated aqueous NH4Cl (100 mL) and dried 
(Na2SO4). The solvent was evaporated to give a yellow oil, which was purified by 
column chromatography on silica gel (84 g), using hexane/AcOEt (12:1) as eluent, to 
give 11 as a colourless oil (1.25 g; Yield 54%). IR (NaCl): υ = 3383, 3030, 2738, 1918, 





(CDCl3):  = - 0.12 (s, 3H, CH3), - 0.04 (s, 3H, CH3), 0.76 (s, 9H, C(CH3)3), 1.84-1.90 
(m, 1H, 2β-H), 2.57-2.66 (m, 1H, 2α-H), 3.28-3.33 (m, 1H, 3β-H), 3.36-3.39 (d, 1H, J(d) 
= 3.45 Hz, exchangeable with D2O), 3.88-3.89 (d, 2H, J(d) = 3.36 Hz, CH2OSi-), 4.99-
5.05 (m, 1H, 1β-H), 7.24-7.31 (m, 3H, ArH), 7.42-7.45 (m, 1H, ArH). 
13
C NMR 
(CDCl3):  = - 5.38 (CH3), - 5.24 (CH3), 18.78 (C), 26.16 (C(CH3)3), 39.81 (CH2), 45.97 
(CH), 67.19 (CH2), 74.98 (CH), 124.51, 125.14, 127.83 and 128.82 (CH), 144.05 (C), 
146.69 (C). Anal. calcd. for C16H26O2Si: C, 69.01; H, 9.41. Found: C, 69.35; H, 9.19. 
( )-trans-3-[(tert-Butyldimethylsilyloxy)methyl]-1-indanyl benzoate, 12. 
To a solution of 11 (1.0 g; 3.59 mmol), benzoic acid (0.62 g; 5.02 mmol) and 
triphenylphosphine (1.10 g; 3.95 mmol) in THF (40 mL) was added dropwise, under an 
argon atmosphere at 0ºC, a solution of DEAD (1.56 mL) in THF (5 mL). The mixture 
was stirred at 0ºC for 1 h and at room temperature for 25 h. Dichloromethane (80 mL) 
and saturated aqueous NaHCO3 (60 mL) were added. The aqueous phase was extracted 
with dichloromethane (3 × 60 mL) and the solvent was removed under reduced pressure 
to give a colourless solid, which was purified by column chromatography on silica gel 
(130 g), using hexane/AcOEt (60:1) as eluent, to give 12 as a colourless liquid (1.03 g; 





H NMR (CDCl3):  = 0.01 (s, 3H, CH3Si-), 0.05 (s, 3H, CH3Si-), 0.89 
(s, 9H, C(CH3)3), 2.33-2.51 (m, 2H, 2α-H and 2β-H), 3.57-3.65 (m, 1H, 3β-H), 3.70-
3.76 (m, 1H, CHHOSi-), 3.83-3.88 (m, 1H, CHHOSi-), 6.48-6.52 (m, 1H, 1β-H), 7.26-
7.57 (m, 2H, ArH), 8.04-8.06 (m, 2H, ArH). 
13
C NMR (CDCl3):  = - 0.51 (CH3), - 4.98 
(CH3), 18.68 (C), 26.29 (CH3), 36.90 (CH2), 46.11 (CH), 67.23 (CH2), 78.53 (CH), 
125.10, 126.02, 127.77, 128.68, 129.28, 130.09, 130.91 and 133.27 (CH), 142.15 (C), 
145.80 (C), 167.02 (C). Anal. calcd. for C23H30O3Si: C, 72.21; H, 7.90. Found: C, 
71.91; H, 8.17. 
 
 
( )-trans-3-[(tert-Butyldimethylsilyloxy)methyl]-1-indanol, 13. 
A solution of 12 (0.5 g; 1.307 mmol) and MeONa (0.5 g; 1.43 mmol) in methanol (20 
mL) was stirred for 16 h under an argon atmosphere at room temperature. The solvent 
was removed under reduced pressure to give a colourless solid, which was purified by 
column chromatography on silica gel (45 g), using hexane/AcOEt (18:1) as eluent, to 
give 13 as a colourless oil (0.280 g; Yield 95%). IR (NaCl): υ = 3345, 3030, 2930, 




H NMR (CDCl3):  = - 0.06 
(s, 3H, CH3), - 0.09 (s, 3H, CH3), 0.83 (s, 9H, C(CH3)3), 2.02-2.10 (m, 1H, 2β-H), 2.28-
2.34 (m, 1H, 2α-H), 3.42-3.48 (m, 1H, 3β-H), 3.60-3.63 (m, 1H, CHHOSi-), 3.70-3.74 
(m, 1H, CHHOSi-), 5.26-5.29 (m, 1H, 1β-H), 7.23-7.31 (m, 3H, ArH), 7.36-7.39 (m, 
1H, ArH). 
13
C NMR (CDCl3):  = 5.50 (CH3), 18.24 (C), 25.84 (CH3), 39.74 (CH2), 
45.39 (CH), 66.91 (CH2), 75.45 (CH), 124.21, 124.91, 127.36 and 128.28 (CH), 144.27 
(C), 145.49 (C). Anal. calcd. for C16H26O2Si: C, 69.01; H, 9.41. Found: C, 69.29; H, 
9.21. 
( )-cis-3-(6-Chloro-9H-purin-9-yl)-1-[(tert-butyldimethylsilyloxy)methyl]indan, 14. 
To a solution of 13 (0.280 g; 1.006 mmol), triphenylphosphine (0.300 g; 1.107 mmol) 
and 6-chloropurine (0.220 g; 1.41 mmol) in THF (20 mL), under an argon atmosphere  
and at 0ºC, was added dropwise a solution of DEAD (0.440 mL; 1.107 mmol) in THF 
(10 mL). The mixture was stirred for 1 h at 0ºC and for 39 h at room temperature. The 
solvent was removed under reduced pressure and the residue was purified by column 
chromatography on silica gel (50 g), using hexane/AcOEt (18:1) as eluent, to give 14 as 





H NMR (CDCl3):  = 0.0016-0.03 (2s, 6H, 2CH3), 0.84 (1s, 9H, C(CH3)3), 
2.11-2.21 (dt, 1H, J(t) = 13.65 Hz, J(d) = 7.36 Hz, 2β-H), 2.98-3.04 (dt, 1H, J(t) = 13.64 
Hz, J(d) = 8.41 Hz, 2α-H), 3.46-3.54 (m, 1H, 1β-H), 4.023-4.13 (m, 2H, CH2OSi-), 6.31-
6.34 (m 1H, 3β-H), 7.01-7.04 (d, 1H, J = 7.51 Hz, ArH), 7.26-7.47 (m, 3H, ArH), 8.00 
(s, 1H, 8'-H), 8.79 (s, 1H, 2'-H). 
13
C NMR (CDCl3):  = 26.25 (CH3), 37.45 (CH2), 
45.83 (CH), 58.69 (CH), 66.05 (CH2), 124.62, 125.41, 128.44 and 129.70 (CH), 132.14 
(C) 132.15 (C trans), 140.28 (C), 144.33 (CH), 144.95 (C), 151.46 (C), 152.32 (CH), 
152.47 (C). Anal. calcd. for C21H27ClN4OSi: C, 60.78; H, 6.56; N, 13.50. Found: C, 
61.09; H, 6.38; N, 13.67. 
 
( )-cis-3-(6-Hydroxy-9H-purin-9-yl)-1-indanylmethanol, 15. 
A solution of 14 (0.060 g; 0.145 mmol) in 1,4-dioxane (15 mL) and 0.25 N NaOH (8 
mL) was stirred for 4 h at room temperature. The solvent was removed under reduced 
pressure and successive coevaporations with toluene were carried out to remove any 
residual solvent. A colourless oil was obtained and this was purified by column 
chromatography on silica gel (12 g), using CH2Cl2/MeOH (30:1) as eluent, to give 15 as 
a colourless solid (0.030 g; Yield 73%). M.p. 168-170ºC. IR (KBr): υ = 3417, 2923, 




H NMR (CDCl3):  = 2.21-2.31 (dt, 
1H, J(t) = 13.43 Hz, J(d) = 7.62 Hz, 2β-H), 2.93-3.03 (dt, 1H, J(t) = 13.43 Hz, J(d) = 8.31 
Hz, 2α-H), 3.45-3.49 (m, 1H, 1β-H), 3.84-3.98 (m, 2H, CH2O), 6.16-6.21 (t, 1H, J(t) = 
8.01 Hz, 3β-H), 7.01-7.03(d, 1H, J(d) = 7.58 Hz, ArH), 7.23-7.28 (t, 1H, J(t) = 7.42 Hz, 
ArH), 7.34-7.39 (t, 1H, J(t) = 7.44 Hz, ArH), 7.46-7.49 (m, 1H, ArH), 7.91 (s, 1H, 2'H), 
8.05 (s, 1H, 8'H). 
13
C NMR (CDCl3):  = 37.99 (CH2), 46.56 (CH), 59.77 (CH), 65.53 
(CH2), 66.18 (CH2), 125.11 (CH), 125.30 (C), 125.77, 128.87 and 130.11 (CH), 140.71 
(CH), 142.19 (C), 145.63 (C), 146.55 (CH), 150.45 (C). Anal. calcd. for C15H14N4O2: C, 
63.82; H, 5.00; N, 19.85. Found: C, 63.66; H, 5.24; N, 19.55. 
( )-cis-3-(6-N-Cyclopropylamino-9H-purin-9-yl)-1-[(tert-butyldimethylsilyloxy)me-
thyl]indan, 16. 
In a pressure reactor, previously purged with argon, was placed a solution of 14 (0.100 
g; 0.241 mmol) and N-cyclopropylamine (0.027 mL; 0.265 mmol) in THF (15 mL) and 
the mixture was stirred for 150 h a 50ºC. The solvent was removed under reduced 
pressure to give a yellow oil, which was purified by column chromatography on silica 
gel (8 g), using CHCl3/isopropanol (60:1) as eluent, to give 16 as a yellow oil (0.070 g; 





(CDCl3):  = - 0.01 (s, 3H, CH3), 0.03 (s, 3H, CH3), 0.83 (s, 9H, C(CH3)3), 1.03-1.05 
(m, 4H, cyclopropyl-(CH2)2), 2.08-2.18 (dt, 1H, J(t) = 13.71 Hz, J(d) = 7.10 Hz, 2β-H), 
2.97-3.07 (dt, 1H, J(t) = 13.71 Hz, J(d) = 8.43 Hz, 2α-H), 3.45-3.54 (m, 3H, 1 -H + 1 -H 
+ -CH-cyclopropyl), 3.87-3.92 (Part A of an ABM system, 1H, JAB = 11.13 Hz, JAM = 
5.28 Hz, -CHHOSi-), 3.92-3.97 (Part B of an ABM system, 1H, JBA = 11.13 Hz, JBM = 
5.27 Hz, -CHHOSi-), 6.18-6.23 (t, 1H, J(t) = 7.62 Hz, 3β-H), 7.04-7.07 (d, 1H, J(d) = 
7.56 Hz, ArH), 7.29-7.42 (m, 3H, ArH), 7.67 (s, 1H, 2'H), 7.82 (s, 1H, 8'H), 8.31 (b.s., 
1H, NH, exchangeable with D2O). 
13
C NMR (CDCl3):  = 25.82 (CH2), 26.09 (CH3), 
37.07 (CH2), 45.45 (CH3), 58.36 (CH2), 65.59 (CH), 124.25, 124.44, 125.01 and 125.34 
(ArH), 128.06 (CH), 128.20 (C), 129.44 (CH), 129.61 (C), 137.37 (C), 154.35 (C). 
Anal. calcd. for C24H33N5OSi: C, 66.17; H, 7.64; N, 16.08. Found: C, 65.81; H, 7.45; N, 
16.38. 
( )-cis-3-(6-N-Cyclopropylamino-9H-purin-9-yl)-1-indanylmethanol, 17. 
To a solution of 16 (0.06 g; 0.147 mmol) in THF (10 mL) was added a mixture of 
TFA/H2O (3:1) (6 mL) and the mixture was stirred for 21 h at room temperature. The 
solvent was removed under reduced pressure and several coevaporations with toluene 
were carried out to remove residual solvent. A yellow oil was obtained and this was 
purified by column chromatography on silica gel (5 g), using CH2Cl2/isopropanol (30:1) 
as eluent, to give 17 as a colourless solid (0.020 g; Yield 42%). IR (KBr): υ = 3394, 




H NMR (CDCl3):  = 0.85-0.97 (m, 4H, 
cyclopropyl-(CH2)2), 2.30-2.40 (dt, 1H, J(t) = 13.94 Hz, J(d) = 7.00 Hz, 2β-H), 2.99-3.10 
(dt, 1H, J(t) = 13.94 Hz, J(d) = 8.87 Hz, 2β-H), 3.14 (m, 1H, cyclopropyl-CH), 3.51-3.59 
(m, 1H, 1β-H), 3.98-4.04 (part A of an ABM system, 1H, JAB = 10.90 Hz, JAM = 4.03 
Hz, -CHHOH), 4.06-4.11 (part B of an ABM system, 1H, JBA = 10.90 Hz, JBM = 4.65 
Hz, -CHHOH), 6.12-6.17 (t, 1H, J(t) = 7.85 Hz, 3β-H), 6.24-6.29 (t, 1H, J(t) = 5.89 Hz, 
3α-H), 7.02-7.05 (d, 1H, J(d) = 7.60 Hz, ArH), 7.22-7.31 (m, 1H, ArH), 7.36-7.47 (m, 
2H, ArH), 7.74 (s, 1H, 8'-H), 8.39 (s, 1H, 2'-H). 
13
C NMR (CDCl3):  = 7.51 (CH2), 
29.76 (CH), 36.08 (CH2), 45.37 (CH), 58.48 (CH), 64.97 (CH2), 119.96 (C), 124.62, 
125.07, 128.10 and 129.41 (CH), 138.67 (C), 139.38 (C), 140.90 (CH), 143.81 (CH), 
144.37 (C). Anal. calcd. for C18H19N5O: C, 67.27; H, 5.96; N, 21.79. Found: C, 67.45; 
H, 6.19; N, 21.46. 
(±)-cis-5-Chloro-1-(3-hydroxymethyl-1-indanyl)-1,2,3,4-tetrahydropyrimidino-2,4-
dione, 19. 
A solution of 18
16
 (32 mg; 0.124 mmol) and NCS (17.5 mg; 0.129 mmol) in DMF (10 
mL) was stirred, under an argon atmosphere, for 1 h at room temperature. The DMF 
was removed under reduced pressure with the aid of repeated coevaporations with 
toluene. The residue was purified by column chromatography on silica gel (16 g), using 
dichloromethane/methanol (40:1) as eluent, to give 19 as a colourless solid (15 mg; 
Yield 25%). M.p. 248ºC (decomposition). IR (KBr): υ = 3546, 3262, 3036, 1689, 1454, 




H NMR (DMSO):  = 1.86-1.98 (dt, 1H, J(t) = 13.67 Hz, 
J(d) = 7.55 Hz, 2' -H), 2.76-2.89 (dt, 1H, J(t) = 13.67 Hz, J(d) = 8.59 Hz, 2' -H), 3.30-
3.39 (m, 1H, 3' -H), 3.85-3.91 (part A of an ABM system, JAB = 10.96 Hz, JAM = 4.29 
Hz, CHHO), 3.94-4.01 (part B of an ABM system, JBA = 10.96 Hz, JBM = 4.79 Hz, 
CHHO), 4.65-5.01 (s, 1H, OH exchangeable with D2O), 6.07-6.14 (t, 1H, J(t) = 7.99 Hz, 
1' -H), 7.13-7.16 (d, 1H, J = 7.21 Hz, ArH), 7.28-7.46 (m, 3H, ArH), 7.58 (s, 1H, 6-H), 
11.65-12.09 (s, 1H, NH exchangeable with D2O). 
13
C NMR (DMSO):  = 34.75 (CH2), 
44.52 (CH), 59.02 (C), 63.57 (CH2), 107.25 (C), 124.33, 124.97, 127.78 and 128.90 
(CH), 139.80 (CH), 140.99 (C), 145.66 (C), 150.92 (C), 159.55 (C). Anal. calcd. for 
C14H13ClN2O3: C, 57.44; H, 4.48; N, 9.57. Found: C, 57.67; H, 4.73; N, 9.69. 
(±)-cis-5-Bromo-1-(3-hydroxymethyl-1-indanyl)-1,2,3,4-tetrahydropyrimidino-2,4-
dione, 20. 
The same procedure as described in section 5.18 was used to prepare compound 20 
from 18 by reaction with NBS. (Yield 73%). M.p. 246ºC (decomposition). IR (KBr): υ 




H NMR (DMSO):  = 
1.83-1.94 (dt, 1H, J(t) = 13.68 Hz, J(d) = 7.52 Hz, 2' -H), 2.72-2.84 (dt, 1H, J(t) = 13.68 
Hz, J(d) = 8.60 Hz, 2' -H), 3.27-3.34 (m, 1H, 3' -H), 3.81-3.87 (part A of an ABM 
system, JAB = 10.98 Hz, JAM = 4.16 Hz, CHHO), 3.90-3.97 (part B of an ABM system, 
JBA = 10.98 Hz, JBM = 4.72 Hz, CHHO), 6.03-6.10 (t, 1H, J(t) = 7.96 Hz, 1' -H), 7.09-
7.12 (d, 1H, J = 7.45 Hz, ArH), 7.24-7.42 (m, 3H, ArH), 7.63 (s, 1H, 6-H), 11.90-12.03 
(s, 1H, NH exchangeable with D2O). 
13
C NMR (DMSO):  = 34.74 (CH2), 44.52 (CH), 
59.02 (CH2), 63.51 (CH), 95.48 (C), 123.98, 124.64, 127.45 and 128.57 (CH), 140.69 
(C), 141.88 (CH), 145.33 (C), 150.78 (C), 159.35 (C). Anal. calcd. for C14H13BrN2O3: 
C, 49.87; H, 3.89; N, 8.31. Found: C, 50.11; H, 3.71; N, 8.46. 
(±)-cis-5-Iodo-1-(3-hydroxymethyl-1-indanyl)-1,2,3,4-tetrahydropyrimidino-2,4-
dione, 21. 
A solution of 18 (32 mg; 0.124 mmol) and NIS (27 mg; 0.129 mmol) in acetic acid (10 
mL) was stirred, under an argon atmosphere, for 36 h at room temperature. The acetic 
acid was removed under reduced pressure and the residue was dissolved in 0.5 M NaOH 
and neutralised with 0.5 M HCl. The material was concentrated under reduced pressure 
and the residue was purified by column chromatography on silica gel (11 g), using 
dichloromethane/methanol (25:1) as eluent, to give 21 as a colourless solid (25 mg; 





H NMR (DMSO):  = 1.75-1.86 (dt, 1H, J(t) = 13.45 Hz, J(d) = 7.61 Hz, 
2' -H), 2.54-2.66 (dt, 1H, J(t) = 13.45 Hz, J(d) = 8.63 Hz, 2' -H), 3.21-3.39 (m, 1H, 3' -
H), 3.70 (b.s., 2H, CH2OH), 4.75 (s, 1H, OH exchangeable with D2O), 5.87-5.93 (t, 1H, 
J(t) = 8.07 Hz, 1' -H), 7.06-7.09 (d, 1H, J = 7.25 Hz, ArH), 7.17-7.29 (m, 2H, ArH), 
7.34-7.37 (d, 1H, J = 7.25 Hz, ArH), 7.61 (s, 1H, 6-H), 10.80 (s, 1H, NH exchangeable 
with D2O). 
13
C NMR (DMSO):  = 35.08 (CH2), 44.87 (CH), 59.21 (CH), 63.79 (CH2), 
69.49 (C), 124.20, 124.97, 127.75 and 128.85 (CH), 141.09 (C), 145.63 (C), 146.82 
(CH), 151.43 (C), 160.98 (C). Anal. calcd. for C14H13IN2O3: C, 43.77; H, 3.41; N, 7.29. 
Found: C, 44.01; H, 3.59; N, 7.13. 
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